
Introducing the next generation microwave ablation device for cancer treatment

Introducing the next generation microwave ablation device for cancer treatment
What they do: Develop a flexible microwave ablation platform for minimally invasive treatment of early-stage lung cancer
Founded: 2019
Latest funding: Series A €5.7M (Sep 4, 2024)
Headcount (approx.): 6
HQ: Suresnes, France
Minimally invasive cancer treatment (early-stage lung cancer)
2019
Medical devices
Seed round led by MD Start (incubator)
€5,700,000
Series A reported closed Sep 4, 2024; reported participants include M&L Healthcare Investments and Cléry